Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bone Biologics (BBLG) Amortization of Deferred Charges (2016 - 2017)

Bone Biologics (BBLG) has disclosed Amortization of Deferred Charges for 2 consecutive years, with $9794.0 as the latest value for Q4 2017.

  • On a quarterly basis, Amortization of Deferred Charges changed 0.02% to $9794.0 in Q4 2017 year-over-year; TTM through Dec 2017 was $39177.0, a 28.76% decrease, with the full-year FY2018 number at $21283.0, down 45.67% from a year prior.
  • Amortization of Deferred Charges was $9794.0 for Q4 2017 at Bone Biologics, roughly flat from $9795.0 in the prior quarter.
  • In the past five years, Amortization of Deferred Charges ranged from a high of $25613.0 in Q1 2016 to a low of $9793.0 in Q3 2016.